Vericel CorpVCELEarnings & Financial Report
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
VCEL Q3 2025 Key Financial Metrics
Revenue
$67.5M
Gross Profit
$49.6M
Operating Profit
$3.5M
Net Profit
$5.1M
Gross Margin
73.5%
Operating Margin
5.1%
Net Margin
7.5%
YoY Growth
16.6%
EPS
$0.10
Financial Flow
Vericel Corp Q3 2025 Financial Summary
Vericel Corp reported revenue of $67.5M for Q3 2025, with a net profit of $5.1M (7.5% margin). Cost of goods sold was $17.9M, operating expenses totaled $46.1M.
Key Financial Metrics
| Total Revenue | $67.5M |
|---|---|
| Net Profit | $5.1M |
| Gross Margin | 73.5% |
| Operating Margin | 5.1% |
| Report Period | Q3 2025 |
Vericel Corp Annual Revenue by Year
Vericel Corp annual revenue history includes year-by-year totals (for example, 2024 revenue was $237.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $237.2M |
| 2023 | $197.5M |
| 2022 | $163.7M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $65.0M | $51.3M | $52.7M | $57.9M | $75.4M | $52.6M | $63.2M | $67.5M |
| YoY Growth | 23.3% | 25.0% | 14.7% | 27.0% | 16.0% | 2.6% | 20.1% | 16.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $353.7M | $356.7M | $376.8M | $390.4M | $432.7M | $424.6M | $435.6M | $453.3M |
| Liabilities | $127.7M | $122.8M | $133.9M | $132.9M | $140.8M | $129.1M | $128.8M | $131.4M |
| Equity | $226.0M | $233.9M | $243.0M | $257.5M | $292.0M | $295.5M | $306.8M | $321.9M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $10.1M | $7.2M | $18.5M | $10.2M | $22.2M | $6.6M | $8.2M | $22.1M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M